Should I buy or sell Seagen stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares. View SGEN analyst ratings or view top-rated stocks .

What is Seagen's stock price target for 2024?

2 equities research analysts have issued twelve-month price targets for Seagen's stock. Their SGEN share price targets range from $229.00 to $229.00. On average, they predict the company's share price to reach $229.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts .

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) released its earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company earned $648.65 million during the quarter, compared to the consensus estimate of $635.10 million. Seagen had a negative trailing twelve-month return on equity of 28.06% and a negative net margin of 32.61%. The company's revenue was up 27.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.03) earnings per share.

What ETFs hold Seagen's stock?

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include VanEck Biotech ETF (BBH) , Invesco Nasdaq Biotechnology ETF (IBBQ) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , iShares Biotechnology ETF (IBB) , Principal Healthcare Innovators ETF (BTEC) , AltShares Merger Arbitrage ETF (ARB) , Goldman Sachs Future Health Care Equity ETF (GDOC) and ProShares Ultra Nasdaq Biotechnology (BIB) .

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com . Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA) , AbbVie (ABBV) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Salesforce (CRM) , QUALCOMM (QCOM) , Tesla (TSLA) , Micron Technology (MU) , Netflix (NFLX) and Alibaba Group (BABA) .

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics. Read More

NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free SGEN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $228.74
▼
$228.74
50-Day Range: $228.74
▼
$228.74
52-Week Range: $123.77
▼
$228.96

Volume: 86 shs
Average Volume: 1.48 million shs
Market Capitalization: $42.93 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $229.00

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media Sustainability

Get Seagen alerts:

Seagen MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.1% Upside
$229.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.86
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.82) to ($1.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.32 out of 5 stars

Medical Sector

902nd out of 929 stocks

Biotechnology Industry

26th out of 28 stocks

1.0

Analyst's Opinion

Consensus Rating
Seagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Seagen has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SGEN.

0.0

Dividend Strength

Dividend Yield
Seagen does not currently pay a dividend.
Dividend Growth
Seagen does not have a long track record of dividend growth.

2.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seagen has received a 13.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.
Environmental Sustainability
The Environmental Impact score for Seagen is -2.86.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Seagen this week, compared to 5 articles on an average week.
Search Interest
3 people have searched for SGEN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

SGEN Stock News Headlines

April 13, 2024 | wsj.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

March 20, 2024 | msn.com

Ron Baron Portfolio Magic: Building Your Financial Future

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 13, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 1, 2024 | bizjournals.com

Pfizer shutting down Seagen's $350M construction project in Everett

February 24, 2024 | finance.yahoo.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 23, 2024 | msn.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 22, 2024 | finance.yahoo.com

MRNA Feb 2024 67.000 put

February 12, 2024 | msn.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 10, 2024 | finance.yahoo.com

PRIMECAP Management's Strategic Exits and New Positions Highlight Q4 Moves

January 29, 2024 | msn.com

Pfizer Q4 results on deck amid gloomy earnings outlook

January 28, 2024 | za.investing.com

Pro Research: Wall Street eyes Seagen's growth trajectory

December 30, 2023 | ca.finance.yahoo.com

SGEN Jan 2024 210.000 put

December 30, 2023 | ca.finance.yahoo.com

SGEN Jan 2024 235.000 put(CONTR

December 30, 2023 | uk.finance.yahoo.com

SGEN Dec 2023 195.000 put(CONTR

December 27, 2023 | za.investing.com

Pro Research: Wall Street dives into Seagen's oncology advances

December 22, 2023 | seekingalpha.com

HBM Gets Health Boost From Drug Licensing Deals

December 14, 2023 | msn.com

Pfizer Shares Slump After Waning Covid Sales Hurt 2024 Outlook

December 13, 2023 | seekingalpha.com

Take-Two Interactive Software to replace Seagen on Nasdaq-100 Index

December 13, 2023 | msn.com

Pfizer to Establish New Oncology Division Following Completion of Seagen Deal

December 13, 2023 | msn.com

Pfizer slips as 2024 guidance with Seagen buyout disappoints

December 12, 2023 | nasdaq.com

Pfizer gets OK for $43-bln Seagen deal after donating cancer drug rights

December 11, 2023 | benzinga.com

What the Options Market Tells Us About Seagen

December 11, 2023 | businesswire.com

88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –

See More Headlines

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:SGEN
CUSIP: 81257810
CIK: 1060736
Web: www.seattlegenetics.com
Phone: (425) 527-4000
Fax: 425-527-4001
Employees: 3,256
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $229.00
High Stock Price Target: $229.00
Low Stock Price Target: $229.00
Potential Upside/Downside: +0.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-610,310,000.00
Net Margins: -32.61%
Pretax Margin: -32.12%
Return on Equity: -28.06%
Return on Assets: -20.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.67
Quick Ratio: 2.12

Sales & Book Value

Annual Sales: $2.30 billion
Price / Sales: 18.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.10 per share
Price / Book: 15.15

Miscellaneous

Outstanding Shares: 187,698,000
Free Float: 139,084,000
Market Cap: $42.93 billion
Optionable: Optionable
Beta: 0.32

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. David R. Epstein B.Sc. (Age 61)
M.B.A., CEO & Director
Comp: $1.39M
Mr. Todd E. Simpson (Age 62)
Chief Financial Officer
Comp: $1.26M
Dr. Vaughn B. Himes Ph.D. (Age 62)
Chief Technical Officer
Comp: $1.08M
Ms. Jean I. Liu J.D. (Age 55)
M.S., Chief Legal Officer & Corporate Secretary
Comp: $1.23M
Mr. Charles R. Romp (Age 55)
Executive Vice President of Commercial U.S.
Comp: $1.08M
Dr. Roger D. Dansey M.D. (Age 67)
Chief Medical Officer and President of Research & Development
Comp: $2.48M
Mr. William Compton
Senior VP of Global Information Technology & CIO
Mr. David Caouette
Vice President of Corporate Communications
Mr. Matt Skelton
Vice President of Marketing
Ms. Peggy M. Pinkston
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.
What is Seagen's stock price target for 2024?: 2 equities research analysts have issued twelve-month price targets for Seagen's stock. Their SGEN share price targets range from $229.00 to $229.00. On average, they predict the company's share price to reach $229.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.
How were Seagen's earnings last quarter?: Seagen Inc. (NASDAQ:SGEN) released its earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company earned $648.65 million during the quarter, compared to the consensus estimate of $635.10 million. Seagen had a negative trailing twelve-month return on equity of 28.06% and a negative net margin of 32.61%. The company's revenue was up 27.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.03) earnings per share.
What ETFs hold Seagen's stock?: ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Principal Healthcare Innovators ETF (BTEC), AltShares Merger Arbitrage ETF (ARB), Goldman Sachs Future Health Care Equity ETF (GDOC) and ProShares Ultra Nasdaq Biotechnology (BIB).

What is Clay B. Siegall's approval rating as Seagen's CEO?: 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Seagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).
Does Seagen have any subsidiaries?: The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More

This page (NASDAQ:SGEN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seagen (SGEN) Stock Price, News & Analysis

Seagen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Seagen Stock (NASDAQ:SGEN)

SGEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SGEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™